Live Earnings Conference Call: Eyepoint Pharmaceuticals will host a live Q1 2026 earnings call on May 6, 2026 at 8:30AM ET. Get details.

Eyepoint Pharmaceuticals (EYPT) Financials

$13.75 -0.10 (-0.72%)

Closing price 05/5/2026 04:00 PM Eastern

Extended Trading

$13.93 +0.18 (+1.28%)

As of 05/5/2026 07:30 PM Eastern

Compare

Annual Income Statements for Eyepoint Pharmaceuticals

This table shows Eyepoint Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2015	6/30/2016	6/30/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	6.35	-22	-18	-86	-57	-91	-58	-102	-71	-131	-232
Consolidated Net Income / (Loss)	6.35	-22	-18	-86	-57	-45	-58	-102	-71	-131	-232
Net Income / (Loss) Continuing Operations	6.35	-22	-18	-86	-57	-91	-58	-102	-71	-131	-232
Total Pre-Tax Income	6.44	-22	-18	-86	-57	-91	-58	-102	-71	-131	-232
Total Operating Income	6.42	-22	-19	-39	-48	-37	-55	-100	-75	-146	-243
Total Gross Profit	27	1.62	7.54	4.57	18	63	29	33	46	43	29
Total Revenue	27	1.62	7.54	4.57	20	69	37	41	46	43	31
Operating Revenue	27	1.62	7.54	4.57	20	69	37	41	46	43	31
Total Cost of Revenue	0.00	0.00	0.00	0.00	2.69	5.82	8.18	8.33	0.00	0.00	2.07
Operating Cost of Revenue	-	-	0.00	-	2.69	5.82	8.18	8.33	-	-	2.07
Total Operating Expenses	20	23	26	44	66	138	84	133	121	189	273
Selling, General & Admin Expense	8.06	9.01	11	15	18	21	26	35	40	52	52
Marketing Expense	-	0.00	0.00	9.66	30	25	28	26	12	0.13	0.09
Research & Development Expense	12	14	15	19	15	17	29	50	65	133	221
Amortization Expense	-	-	0.00	0.00	2.46	-	2.46	2.05	0.00	0.00	0.00
Impairment Charge	-	-	-	-	-	-	0.00	21	0.00	0.00	0.00
Total Other Income / (Expense), net	0.02	0.07	0.09	-47	-8.93	-16	-3.14	-2.62	4.36	15	12
Interest Expense	-	0.00	0.00	2.36	9.99	8.16	3.43	4.75	2.59	0.01	0.03
Other Income / (Expense), net	0.02	0.07	0.09	-45	1.05	-8.05	0.29	2.13	6.95	15	12
Income Tax Expense	0.10	-0.16	-	-	-	-	-	0.00	0.08	0.09	0.28
Basic Earnings per Share	$0.22	($0.68)	($0.52)	($1.27)	($5.44)	($3.54)	($2.03)	($2.74)	($1.82)	($2.32)	($3.17)
Weighted Average Basic Shares Outstanding	29.38M	31.62M	35.34M	67.94M	10.43M	12.84M	28.76M	37.32M	38.90M	56.30M	73.25M
Diluted Earnings per Share	$0.21	($0.68)	($0.52)	($1.27)	($5.44)	($3.54)	($2.03)	($2.74)	($1.82)	($2.32)	($3.17)
Weighted Average Diluted Shares Outstanding	30.58M	31.62M	35.34M	67.94M	10.43M	12.84M	28.76M	37.32M	38.90M	56.30M	73.25M
Weighted Average Basic & Diluted Shares Outstanding	28.90M	31.62M	35.34M	67.94M	10.43M	12.84M	28.76M	34.30M	49.83M	68.73M	83.43M

This table shows Eyepoint Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-23	-13	-14	-29	-31	-29	-41	-45	-59	-60	-68
Consolidated Net Income / (Loss)	-23	-13	-14	-29	-31	-29	-41	-45	-59	-60	-68
Net Income / (Loss) Continuing Operations	-23	-13	-14	-29	-31	-29	-41	-45	-59	-60	-68
Total Pre-Tax Income	-23	-13	-14	-29	-31	-29	-41	-45	-59	-60	-67
Total Operating Income	-23	-14	-16	-33	-35	-33	-45	-49	-62	-62	-70
Total Gross Profit	7.31	14	18	11	9.48	9.79	14	24	5.33	0.97	-1.45
Total Revenue	9.11	15	14	12	9.48	11	12	24	5.33	0.97	0.62
Operating Revenue	9.11	15	14	12	9.48	11	12	24	5.33	0.97	0.62
Total Cost of Revenue	1.79	1.20	-3.63	0.76	0.00	0.74	-2.90	0.00	0.00	0.00	2.07
Total Operating Expenses	30	28	34	44	44	43	60	73	68	63	69
Selling, General & Admin Expense	9.06	11	11	14	13	13	13	14	12	14	11
Marketing Expense	5.29	0.48	0.19	0.01	0.05	0.02	0.05	0.04	0.04	0.03	-0.01
Research & Development Expense	16	17	18	30	30	30	43	59	55	48	59
Total Other Income / (Expense), net	-0.16	1.79	2.34	4.04	3.72	3.39	3.93	3.64	2.89	2.29	2.92
Other Income / (Expense), net	1.62	1.79	2.34	4.04	3.72	3.39	3.94	3.64	2.89	2.29	2.96
Basic Earnings per Share	($0.61)	($0.33)	($0.32)	($0.55)	($0.58)	($0.54)	($0.65)	($0.65)	($0.85)	($0.85)	($0.82)
Weighted Average Basic Shares Outstanding	37.58M	38.34M	38.90M	52.91M	53.21M	54.45M	56.30M	69.77M	69.93M	70.17M	73.25M
Diluted Earnings per Share	($0.61)	($0.33)	($0.32)	($0.55)	($0.58)	($0.54)	($0.65)	($0.65)	($0.85)	($0.85)	($0.82)
Weighted Average Diluted Shares Outstanding	37.58M	38.34M	38.90M	52.91M	53.21M	54.45M	56.30M	69.77M	69.93M	70.17M	73.25M
Weighted Average Basic & Diluted Shares Outstanding	34.98M	35.31M	49.83M	52.08M	53.52M	68.25M	68.73M	68.81M	68.93M	82.79M	83.43M

This table details how cash moves in and out of Eyepoint Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2015	6/30/2016	6/30/2017	6/30/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	3.79	-3.81	1.59	22	-23	23	134	-83	186	-182	2.12
Net Cash From Operating Activities	10	-16	-20	-22	-57	-14	-50	-65	1.88	-126	-240
Net Cash From Continuing Operating Activities	10	-16	-20	-22	-57	-14	-50	-65	1.88	-126	-240
Net Income / (Loss) Continuing Operations	6.35	-22	-18	-53	-57	-45	-58	-102	-71	-131	-232
Consolidated Net Income / (Loss)	6.35	-22	-18	-53	-57	-45	-58	-102	-71	-131	-232
Depreciation Expense	0.11	0.15	0.09	0.17	0.14	0.19	0.31	0.40	0.46	1.54	2.31
Amortization Expense	0.87	0.84	-4.87	1.19	3.06	3.21	3.09	1.49	-0.86	-5.95	-4.83
Non-Cash Adjustments To Reconcile Net Income	1.96	2.16	2.46	29	9.48	7.43	6.66	38	14	38	28
Changes in Operating Assets and Liabilities, net	1.01	2.07	0.32	0.93	-13	20	-1.74	-3.09	59	-29	-34
Net Cash From Investing Activities	-6.73	-4.46	14	-17	-0.21	-0.36	-33	-17	-3.32	-219	69
Net Cash From Continuing Investing Activities	-6.73	-4.46	14	-17	-0.21	-0.36	-33	-17	-3.32	-219	69
Purchase of Property, Plant & Equipment	-0.16	-0.11	-0.15	-0.11	-0.21	-0.36	-0.16	-2.15	-3.48	-4.05	-3.28
Purchase of Investments	-10	-18	-5.05	0.00	-	0.00	-33	-139	-55	-398	-252
Sale of Property, Plant & Equipment	0.00	0.00	0.03	0.00	-	-	-	-	-	0.00	0.16
Sale and/or Maturity of Investments	3.65	13	19	0.00	-	-	0.00	124	55	183	324
Net Cash From Financing Activities	0.24	17	8.50	61	34	37	217	-0.69	187	164	174
Net Cash From Continuing Financing Activities	0.24	17	8.50	61	34	37	217	-0.69	187	164	174
Repayment of Debt	-	0.00	0.00	-1.35	-24	-15	0.00	-74	-47	0.00	0.00
Repurchase of Common Equity	-	-	-	-	-	-	0.00	-0.60	-0.45	-0.67	-0.54
Issuance of Debt	-	0.00	0.00	20	50	-	0.00	74	5.30	0.00	0.00
Issuance of Common Equity	0.00	17	8.40	42	23	50	217	0.00	226	163	173
Other Financing Activities, net	0.24	0.49	0.10	0.50	-15	2.20	0.08	-0.04	3.17	1.38	0.75
Effect of Exchange Rate Changes	-0.01	-0.02	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00
Cash Interest Paid	-	0.00	0.00	0.26	4.87	5.51	4.85	2.60	1.41	0.00	0.00

This table details how cash moves in and out of Eyepoint Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Change in Cash & Equivalents	34	-6.56	148	-10	-180	-11	20	-15	-14	3.43	27
Net Cash From Operating Activities	57	-15	-23	-31	-20	-39	-36	-53	-63	-59	-65
Net Cash From Continuing Operating Activities	57	-15	-23	-31	-20	-39	-36	-53	-63	-59	-65
Net Income / (Loss) Continuing Operations	-23	-13	-14	-29	-31	-29	-41	-45	-59	-60	-68
Consolidated Net Income / (Loss)	-23	-13	-14	-29	-31	-29	-41	-45	-59	-60	-68
Depreciation Expense	0.13	0.12	0.11	0.30	0.36	0.41	0.47	0.50	0.54	0.58	0.70
Amortization Expense	-0.05	-0.04	-0.52	-0.58	-1.69	-1.88	-1.81	-1.73	-1.20	-0.95	-0.94
Non-Cash Adjustments To Reconcile Net Income	3.64	4.10	3.12	13	8.70	7.45	7.90	8.30	6.40	6.95	6.73
Changes in Operating Assets and Liabilities, net	76	-6.76	-12	-15	3.28	-16	-1.01	-15	-8.90	-6.20	-3.92
Net Cash From Investing Activities	13	-1.72	-47	21	-160	16	-96	40	48	55	-75
Net Cash From Continuing Investing Activities	13	-1.72	-47	21	-160	16	-96	40	48	55	-75
Purchase of Property, Plant & Equipment	-0.40	-1.72	-0.88	-1.19	-0.90	-1.57	-0.38	-0.28	-1.22	-0.80	-0.99
Purchase of Investments	-2.92	-	-49	0.00	-185	-49	-164	-39	-54	-9.82	-149
Sale and/or Maturity of Investments	17	-	3.00	22	26	67	69	79	104	66	75
Net Cash From Financing Activities	-37	10	218	0.12	0.33	12	152	-0.95	0.24	7.40	167
Net Cash From Continuing Financing Activities	-37	10	218	0.12	0.33	12	152	-0.95	0.24	7.40	167
Repurchase of Common Equity	-	-0.42	-0.04	-0.09	0.09	-0.31	-0.37	-0.29	-	-	-0.25
Issuance of Common Equity	-	9.97	216	0.00	-	12	152	0.00	-	6.66	167
Other Financing Activities, net	-0.01	0.80	2.32	0.20	0.55	0.17	0.46	-0.66	0.29	0.69	0.42

This table presents Eyepoint Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2015	6/30/2016	6/30/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	32	32	19	78	73	92	263	180	355	418	364
Total Current Assets	30	30	18	48	42	63	238	173	345	383	329
Cash & Equivalents	19	15	17	45	22	45	179	96	281	100	102
Short-Term Investments	9.41	14	-	-	-	0.00	33	49	50	271	204
Accounts Receivable	0.62	0.49	0.25	0.63	11	9.45	18	16	0.81	0.61	0.65
Inventories, net	-	-	0.00	0.28	2.14	5.34	3.62	2.89	3.91	2.31	1.81
Prepaid Expenses	0.68	0.48	0.59	1.43	6.00	3.42	4.22	9.86	9.04	9.48	20
Plant, Property, & Equipment, net	0.34	0.29	0.31	0.29	0.36	0.63	0.48	1.36	5.25	8.18	9.02
Total Noncurrent Assets	2.19	1.37	0.62	30	31	28	25	6.19	5.13	27	26
Intangible Assets	1.93	1.10	0.36	30	28	25	23	0.00	0.00	0.00	0.00
Other Noncurrent Operating Assets	0.12	0.11	0.11	0.00	3.08	2.61	2.25	6.04	4.98	27	26
Other Noncurrent Nonoperating Assets	0.15	0.15	0.15	0.15	0.15	0.15	0.15	0.15	0.15	0.15	0.15
Total Liabilities & Shareholders' Equity	32	32	19	78	73	92	263	180	355	418	364
Total Liabilities	9.00	11	5.34	41	65	73	79	84	89	82	58
Total Current Liabilities	3.35	5.09	5.29	21	12	15	24	35	63	49	37
Short-Term Debt	-	-	-	-	-	-	0.00	10	0.00	0.00	0.00
Accounts Payable	0.74	1.36	1.02	2.64	4.19	4.81	7.39	5.92	6.50	12	10
Accrued Expenses	2.57	3.58	4.22	19	6.83	8.45	14	16	18	18	24
Current Deferred Revenue	0.03	0.15	0.05	0.03	0.02	0.95	1.07	1.21	39	18	0.00
Other Current Liabilities	-	-	-	0.00	0.48	0.69	0.78	0.58	0.65	1.44	2.14
Total Noncurrent Liabilities	5.65	5.65	0.05	19	53	58	55	49	26	33	21
Long-Term Debt	-	-	0.00	18	47	38	37	29	0.00	0.00	0.00
Noncurrent Deferred Revenue	5.65	5.65	-	-	0.00	16	15	14	21	11	0.00
Other Noncurrent Operating Liabilities	-	-	0.05	1.46	5.90	4.70	4.21	6.58	4.91	22	21
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	23	21	13	38	8.33	19	184	96	266	337	306
Total Preferred & Common Equity	23	21	13	38	8.33	19	184	96	266	337	306
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	23	21	13	38	8.33	19	184	96	266	337	306
Common Stock	293	312	323	445	473	528	753	767	1,008	1,208	1,410
Retained Earnings	-271	-292	-311	-408	-465	-511	-569	-671	-742	-873	-1,105
Accumulated Other Comprehensive Income / (Loss)	0.95	0.85	0.83	0.84	0.84	0.84	0.84	0.79	0.86	1.03	0.96

This table presents Eyepoint Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025
Total Assets	220	155	176	160	329	324	301	363	301	252
Total Current Assets	192	146	167	150	318	295	269	327	265	216
Cash & Equivalents	75	106	140	133	271	91	80	85	71	75
Short-Term Investments	82	17	2.94	2.98	28	189	174	233	185	129
Accounts Receivable	21	10	11	0.48	3.02	1.38	0.38	0.44	0.63	1.05
Inventories, net	3.53	4.07	4.26	4.58	4.26	3.67	2.81	2.13	2.68	2.11
Prepaid Expenses	10	9.08	9.37	9.09	11	9.64	12	6.22	6.22	8.93
Plant, Property, & Equipment, net	1.02	2.61	2.87	4.48	6.68	6.90	8.39	8.04	8.76	8.86
Total Noncurrent Assets	27	5.93	5.66	5.40	4.86	22	24	28	27	27
Intangible Assets	21	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Noncurrent Operating Assets	6.32	5.78	5.51	5.25	4.71	22	24	27	27	27
Other Noncurrent Nonoperating Assets	0.15	0.15	0.15	0.15	0.15	0.15	0.15	0.15	0.15	0.15
Total Liabilities & Shareholders' Equity	220	155	176	160	329	324	301	363	301	252
Total Liabilities	84	76	118	101	79	96	82	64	55	52
Total Current Liabilities	34	27	69	64	63	62	49	42	33	30
Short-Term Debt	10	5.30	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable	6.11	9.45	11	9.58	7.08	14	7.34	16	20	10
Accrued Expenses	16	10	15	13	16	13	14	18	11	18
Current Deferred Revenue	1.17	1.24	42	40	38	33	26	5.12	0.00	0.00
Other Current Liabilities	0.50	0.77	0.97	1.06	1.18	1.13	1.29	1.97	2.01	2.08
Total Noncurrent Liabilities	50	49	49	38	17	34	33	22	22	21
Long-Term Debt	29	29	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Noncurrent Deferred Revenue	14	13	44	32	12	12	11	0.00	0.00	0.00
Other Noncurrent Operating Liabilities	6.84	6.32	5.46	5.19	4.62	22	22	22	22	21
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	136	78	57	59	250	228	219	298	246	200
Total Preferred & Common Equity	136	78	57	59	250	228	219	298	246	200
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	136	78	57	59	250	228	219	298	246	200
Common Stock	764	770	772	786	1,021	1,030	1,049	1,216	1,223	1,237
Retained Earnings	-628	-693	-715	-728	-771	-802	-832	-918	-978	-1,037
Accumulated Other Comprehensive Income / (Loss)	0.65	0.84	0.84	0.84	0.84	0.79	1.17	0.92	0.83	0.92

This table displays calculated financial ratios and metrics derived from Eyepoint Pharmaceuticals' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2015	6/30/2016	6/30/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	29,412,365.00	34,172,919.00	39,268,692.00	94,855,705.00	108,117,440.00	143,515,338.00	28,771,264.00	-	-	-	82,787,220.00
DEI Adjusted Shares Outstanding	2,941,236.00	3,417,292.00	3,926,869.00	9,485,570.00	10,811,744.00	14,351,534.00	28,771,264.00	-	-	-	82,787,220.00
DEI Earnings Per Adjusted Shares Outstanding	2.16	-6.31	-4.71	-9.08	-5.25	-6.33	-2.03	-	-	-	-2.80
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	6.33	-15	-13	-27	-34	-26	-39	-70	-53	-102	-170
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-19.73%	-30.34%	-55.67%
Earnings before Interest and Taxes (EBIT)	6.44	-22	-18	-84	-47	-45	-55	-98	-68	-131	-232
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	7.42	-21	-23	-82	-44	-42	-52	-96	-69	-135	-234
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	8.14	-12	-18	-41	-57	-4.37	-36	-52	3.77	-132	-205
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-5.32	-8.26	-3.71	9.84	33	11	9.23	-8.56	-65	-35	-0.12
Increase / (Decrease) in Invested Capital	-1.81	-2.94	4.55	14	23	-22	-2.23	-18	-56	30	34
Book Value per Share	$0.79	$0.61	$0.34	$0.40	$0.08	$0.13	$6.41	$2.83	$7.54	$4.93	$3.70
Tangible Book Value per Share	$0.73	$0.58	$0.33	$0.08	($0.18)	($0.05)	$5.62	$2.83	$7.54	$4.93	$3.70
Total Capital	23	21	13	55	56	57	221	136	266	337	306
Total Debt	0.00	0.00	0.00	18	47	38	37	40	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	18	47	38	37	29	0.00	0.00	0.00
Net Debt	-29	-29	-17	-28	25	-6.93	-175	-105	-331	-371	-306
Capital Expenditures (CapEx)	0.16	0.11	0.11	0.11	0.21	0.36	0.16	2.15	3.48	4.05	3.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-2.05	-4.12	-4.45	-19	7.98	3.32	2.53	4.19	-50	-37	-14
Debt-free Net Working Capital (DFNWC)	26	25	12	26	30	48	214	149	282	334	292
Net Working Capital (NWC)	26	25	12	26	30	48	214	138	282	334	292
Net Nonoperating Expense (NNE)	-0.02	6.31	5.48	59	23	19	20	33	18	29	62
Net Nonoperating Obligations (NNO)	-29	-29	-17	-28	25	-7.08	-175	-105	-331	-371	-306
Total Depreciation and Amortization (D&A)	0.98	1.00	-4.78	1.36	3.20	3.39	3.40	1.89	-0.39	-4.41	-2.52
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$2.20	($6.80)	($5.20)	($11.50)	($5.40)	($3.54)	($2.03)	($2.74)	($1.82)	($2.32)	($3.17)
Adjusted Weighted Average Basic Shares Outstanding	2.94M	3.16M	3.53M	7.45M	12.47M	28.74M	34.04M	37.32M	38.90M	56.30M	73.25M
Adjusted Diluted Earnings per Share	$2.10	($6.80)	($5.20)	($11.50)	($5.40)	($3.54)	($2.03)	($2.74)	($1.82)	($2.32)	($3.17)
Adjusted Weighted Average Diluted Shares Outstanding	3.06M	3.16M	3.53M	7.45M	12.47M	28.74M	34.04M	37.32M	38.90M	56.30M	73.25M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($5.20)	($11.50)	($5.40)	($3.54)	($2.03)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	2.94M	3.42M	3.94M	4.62M	10.43M	12.84M	28.76M	34.30M	49.83M	68.73M	83.43M
Normalized Net Operating Profit after Tax (NOPAT)	6.33	-15	-13	-27	-34	-26	-39	-55	-53	-102	-170
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-

This table displays calculated financial ratios and metrics derived from Eyepoint Pharmaceuticals' official financial filings.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
DEI Shares Outstanding	-	-	-	-	-	-	-	68,728,760.00	68,811,736.00	68,927,425.00	82,787,220.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	68,728,760.00	68,811,736.00	68,927,425.00	82,787,220.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-0.66	-0.86	-0.87	-0.82
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	-16	-10	-11	-23	-24	-23	-32	-34	-44	-43	-49
Return On Investment Capital (ROIC_SIMPLE)	-	-	-4.30%	-	-	-	-9.41%	-11.46%	-17.71%	-21.69%	-16.09%
Earnings before Interest and Taxes (EBIT)	-21	-13	-14	-29	-31	-29	-41	-45	-59	-60	-67
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-21	-13	-14	-30	-32	-31	-43	-46	-60	-60	-68
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	89	86	45	17	-58	-65	-62	-64	-86	-75	-84
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-85	-78	-65	-50	-52	-35	-35	-20	-9.87	-3.99	-0.12
Increase / (Decrease) in Invested Capital	-105	-96	-56	-40	33	42	30	30	42	31	34
Book Value per Share	$1.67	$1.68	$7.54	$5.02	$4.38	$4.09	$4.93	$4.34	$3.58	$2.90	$3.70
Tangible Book Value per Share	$1.67	$1.68	$7.54	$5.02	$4.38	$4.09	$4.93	$4.34	$3.58	$2.90	$3.70
Total Capital	57	59	266	250	228	219	337	298	246	200	306
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-143	-136	-331	-299	-280	-254	-371	-318	-256	-204	-306
Capital Expenditures (CapEx)	0.40	1.72	0.88	1.19	0.90	1.57	0.38	0.28	1.22	0.80	0.99
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-44	-50	-50	-44	-47	-34	-37	-33	-24	-18	-14
Debt-free Net Working Capital (DFNWC)	98	86	282	255	233	220	334	285	232	186	292
Net Working Capital (NWC)	98	86	282	255	233	220	334	285	232	186	292
Net Nonoperating Expense (NNE)	6.99	2.53	2.65	5.96	6.64	6.44	9.73	11	16	16	18
Net Nonoperating Obligations (NNO)	-143	-136	-331	-299	-280	-254	-371	-318	-256	-204	-306
Total Depreciation and Amortization (D&A)	0.08	0.08	-0.41	-0.27	-1.33	-1.47	-1.34	-1.24	-0.66	-0.38	-0.25
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.61)	($0.33)	($0.32)	($0.55)	($0.58)	($0.54)	($0.65)	($0.65)	($0.85)	($0.85)	($0.82)
Adjusted Weighted Average Basic Shares Outstanding	37.58M	38.34M	38.90M	52.91M	53.21M	54.45M	56.30M	69.77M	69.93M	70.17M	73.25M
Adjusted Diluted Earnings per Share	($0.61)	($0.33)	($0.32)	($0.55)	($0.58)	($0.54)	($0.65)	($0.65)	($0.85)	($0.85)	($0.82)
Adjusted Weighted Average Diluted Shares Outstanding	37.58M	38.34M	38.90M	52.91M	53.21M	54.45M	56.30M	69.77M	69.93M	70.17M	73.25M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	34.98M	35.31M	49.83M	52.08M	53.52M	68.25M	68.73M	68.81M	68.93M	82.79M	83.43M
Normalized Net Operating Profit after Tax (NOPAT)	-16	-10	-11	-23	-24	-23	-32	-34	-44	-43	-49
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-

Financials Breakdown Chart

Key Financial Trends

Here are the key takeaways from EyePoint Pharmaceuticals (NASDAQ: EYPT) quarterly filings, focusing on the last four years of data and highlighting trends through Q4 2025.

No long-term debt on recent balance sheets: Long-Term Debt is reported as 0.0 in recent quarters, reducing interest burden and leverage risk.
Material equity financing in Q4 2025: Issuance of Common Equity totaled $166,787,000, expanding EyePoint’s equity base.
Strong financing activity in Q4 2025: Net cash from financing activities was +$166,957,000, driven by equity issuance and related financing.
Solid equity cushion: Total Common Equity around $200.2M (about $200,182,000) in the latest period, indicating a sizable equity base relative to liabilities.
Near-term liquidity improved in Q4 2025: Net change in cash for the quarter was +$27,244,000, aided by financing inflows.
Revenue remains modest and volatile: Operating revenue in Q4 2025 was $0.619M, with quarterly revenue varying significantly across 2023–2025, suggesting no clear, stable top-line trajectory.
Investing cash flows show timing-driven variability: Cash flows from investing activities swing between inflows and outflows across quarters, reflecting asset sales and purchases rather than a steady pattern.
Earnings per share trend remains negative: Basic and diluted EPS are negative across recent quarters (for example, about -$0.82 in Q4 2025 and -$0.85 in Q3 2025), signaling ongoing losses per share.
Persistent net losses: Net income / loss from continuing operations was -$67.6M in Q4 2025, -$59.7M in Q3 2025, -$59.4M in Q2 2025, and -$45.2M in Q1 2025.
Operating cash flow remains negative: Net cash from continuing operating activities was -$65.0M in Q4 2025 (and similarly negative in prior quarters), indicating ongoing cash burn from operations.
Bottom-line profitability and near-term cash burn: The company continues to post losses at the net income line, with negative pretax income in multiple quarters and substantial cash outflows from operations.

05/06/26 01:39 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Eyepoint Pharmaceuticals' Financials

When does Eyepoint Pharmaceuticals' fiscal year end?

According to the most recent income statement we have on file, Eyepoint Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has Eyepoint Pharmaceuticals' net income changed over the last 10 years?

Eyepoint Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$231.96 million in 2025, falling from $6.35 million in 2015. The previous period was -$130.87 million in 2024. See Eyepoint Pharmaceuticals' forecast for analyst expectations on whatâ€™s next for the company.

What is Eyepoint Pharmaceuticals' operating income?

Eyepoint Pharmaceuticals' total operating income in 2025 was -$243.43 million, based on the following breakdown:

Total Gross Profit: $29.31 million
Total Operating Expenses: $272.74 million

How has Eyepoint Pharmaceuticals' revenue changed over the last 10 years?

Over the last 10 years, Eyepoint Pharmaceuticals' total revenue changed from $26.57 million in 2015 to $31.37 million in 2025, a change of 18.1%.

How much debt does Eyepoint Pharmaceuticals have?

Eyepoint Pharmaceuticals' total liabilities were at $57.88 million at the end of 2025, a 29.4% decrease from 2024, and a 543.2% increase since 2015.

How much cash does Eyepoint Pharmaceuticals have?

In the past 10 years, Eyepoint Pharmaceuticals' cash and equivalents has ranged from $15.31 million in 2016 to $281.26 million in 2023, and is currently $101.82 million as of their latest financial filing in 2025.

How has Eyepoint Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, Eyepoint Pharmaceuticals' book value per share changed from 0.79 in 2015 to 3.70 in 2025, a change of 365.4%.

Related Companies

Financial statements for NASDAQ:EYPT last updated on 4/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eyepoint Pharmaceuticals (EYPT) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Eyepoint Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eyepoint Pharmaceuticals (EYPT) Financials

Annual Income Statements for Eyepoint Pharmaceuticals

Quarterly Income Statements for Eyepoint Pharmaceuticals

Annual Cash Flow Statements for Eyepoint Pharmaceuticals

Quarterly Cash Flow Statements for Eyepoint Pharmaceuticals

Annual Balance Sheets for Eyepoint Pharmaceuticals

Quarterly Balance Sheets for Eyepoint Pharmaceuticals

Annual Metrics And Ratios for Eyepoint Pharmaceuticals

Quarterly Metrics And Ratios for Eyepoint Pharmaceuticals

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Eyepoint Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools